

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number  
WO 01/09181 A1

(51) International Patent Classification<sup>7</sup>: C07K 14/47,  
C12N 11/00, B82B 1/00, H02N 6/00, B23Q 1/56

(21) International Application Number: PCT/US00/20925

(22) International Filing Date: 31 July 2000 (31.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/146,975 3 August 1999 (03.08.1999) US

(71) Applicant (for all designated States except US): THE  
GOVERNMENT OF THE UNITED STATES OF  
AMERICA, as represented by THE SECRETARY,  
DEPARTMENT OF HEALTH & HUMAN SER-  
VICES, THE NATIONAL INSTITUTES OF HEALTH  
[US/US]; Office of Technology Transfer, Suite 325, 6011  
Executive Boulevard, Rockville, MD 20852 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SCHNEIDER,  
Thomas, D. [US/US]; 107 Alessandra Court, #208, Fred-  
erick, MD 21702-4015 (US).

(74) Agent: NOONAN, William, D.; Klarquist, Sparkman,  
Campbell, Leigh & Whinston, LLP, Suite 1600 - One World  
Trade Center, 121 S.W. Salmon Street, Portland, OR 97204  
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 01/09181 A1

(54) Title: MOLECULAR MOTOR

(57) Abstract: A molecular motor in which multiple concentric cylinders (or nested cones) rotate around a common longitudinal axis. Opposing complementary surfaces of the cylinders or cones are coated with complementary motor protein pairs (such as actin and myosin). The actin and myosin interact with one another in the presence of ATP to rotate the cylinders or cones relative to one another, and this rotational energy is harnessed to produce work. The concentration of ATP and the number of nested cylinders or cones can be used to control the rotational speed of the motor. The length of the cylinders can also be used to control the power generated by the motor.

## MOLECULAR MOTOR

### FIELD OF THE INVENTION

This invention relates to molecular motors, and particularly such motors  
5 that are powered by proteins.

### BACKGROUND OF THE INVENTION

One of the fundamental properties of biological organisms is the ability  
to move, or to at least transport cellular components, even on a molecular scale. The  
10 biological structure that permits macroscopic movement in animals is muscle, which  
can be either striated (skeletal), smooth, or cardiac. The molecular structure and  
function of muscle has been the subject of scientific fascination and research for  
over a century. As early as the 1840s, William Bowman had suggested that  
striations in skeletal muscle represented bands of intracellular material with differing  
15 refractive indices. These intracellular materials were eventually identified as actin  
and myosin.

The contractile unit in skeletal muscle is known as a myofibril, which  
consists of a series of Z-disks to which are attached thin filaments of actin. The Z-  
disks divide each myofibril into repeating units called sarcomeres, and within each  
20 sarcomere is a thick filament of myosin which has heads that can form crossbridges  
to the actin. In the presence of ATP, the myosin heads undergo a conformational  
change that causes the cross bridges to link to the actin, and the myosin heads move  
the actin filaments relative to the myosin filaments. This movement brings the Z-  
disks closer together, which on a macroscopic level contracts (shortens) the muscle,  
25 and implements musculoskeletal function. Although cardiac and smooth muscle  
differ in their cellular architecture from skeletal muscle, they too rely on the  
interaction of myosin and actin to contract.

The myosin molecule consists of six polypeptide subunits: two identical  
heavy chains with a molecular weight of about 200,000 kDa each, and four light  
30 chains of about 20 kDa each. In electron micrographs, purified myosin looks like a

- 2 -

long thin rod containing two globular heads protruding at one end. This two-headed type of myosin is called myosin II to distinguish it from the smaller, single headed myosin I molecule (having a shorter tail) that is involved in cytoplasmic movements in some nonmuscle cells. The functions of portions of the myosin molecule have  
5 been investigated by using the protease trypsin to cleave the myosin II molecule into two fragments called light meromyosin (a coiled tail portion) and heavy meromyosin (which contains the globular heads of the molecule, and a portion of the coiled tail). The function of actin and myosin, and their molecular structure, are more fully described in Kendrew, *The Encyclopedia of Molecular Biology*, 1994, pages 688-  
10 691; and Kleinsmith and Kish, *Principles of Cell and Molecular Biology*, second edition, 1995, chapter 13, which are incorporated by reference.

A variety of motor proteins other than actin and myosin are also known. The motor protein kinesin, for example, was discovered in 1985 in squid axoplasm. Vale et al., *Cell* 42:39-50, 1985. Kinesin is just one member of a very large family  
15 of motor proteins. Endow, *Trends Biochem. Sci.* 16:221-225, 1991; Goldstein, *Trends Cell Biol.* 1:93, 1991; Stewart et al., *Proc. Natl. Acad. Sci. USA* 88:8470-8474, 1991. Another such motor protein is dynein. Li et al., *J. Cell Biol.* 126:1475-1493, 1994. Kinesin, dynein, and related proteins move along microtubules, whereas myosin moves along actin filaments. Like myosin, kinesin is activated by  
20 ATP.

Kinesin is composed of two heavy chains (each about 120 kDa) and two light chains (each about 60 kDa). The kinesin heavy chains include three structural domains: (a) an amino-terminal head domain, which contains the sites for ATP and microtubule binding and for motor activity; (b) a middle or stalk domain, which may  
25 form an  $\alpha$ -helical coiled coil that entwines two heavy chains to form a dimer; and (c) a carboxyl-terminal domain, which probably forms a globular tail that interacts with the light chains and possibly with vesicles and organelles. Kinesin and kinesin-like proteins are all related by sequence similarity within an approximately 340-amino acid region of the head domain, but outside of this conserved region they show no  
30 sequence similarity.

- 3 -

Purified motor proteins are capable of generating movement even outside biological organisms. The motility activity of purified kinesin on microtubules has, for example, been demonstrated *in vitro*. Vale et al., *Cell* 42:39-50, 1985. Full-length kinesin heavy chain and several types of truncated kinesin heavy chain molecules  
5 produced in *E. coli* are also capable of generating *in vitro* microtubule motility. Yang et al., *Science* 249:42-47, 1990; Stewart et al., *Proc. Natl. Acad. Sci. USA* 90:5209-5213, 1993. The kinesin motor domain has also been shown to retain motor activity *in vitro* after genetic fusion to several other proteins including spectrin (Yang et al.), glutathione S-transferase (Stewart et al.), and biotin carboxyl  
10 carrier protein (Berliner, 269 *J. Biol. Chem.* 269:8610-8615, 1994).

Similarly, methods have been developed for purification or recombinant production and manipulation of motor proteins, and methods of attaching actin to non-biological substrates are also known. Ishima et al., *Cell* 92:161-171, 1998. Microtubules can be routinely reassembled *in vitro* from tubulin purified from  
15 bovine brains. The nucleation, assembly, and disassembly reactions of microtubules have been well characterized. Cassimeris et al., *Bioessays* 7:149-154, 1987. More recently, recombinant tubulin has been produced in yeast. Davis et al., *Biochemistry* 32:8823-8835, 1993.

Efforts have been made in the past to harness the molecular activity of  
20 motor proteins for useful work outside of biological organisms. U.S. Patent No. 5,830,659, for example, disclosed a system for purifying a molecule of interest from a mixture by aligning microtubules in a separation channel leading out of a liquid reservoir. A kinesin-ligand complex was then added to the liquid reservoir, in the presence of ATP, and the ligand was selected to bind to the molecule of interest in  
25 the liquid. When the kinesin came into contact with the microtubules in the channel, the kinesin-ligand (and its bound molecule of interest) were transported through the channel into a collection reservoir, so that the molecule of interest was purified away from the mixture.

Another motor protein device is shown in Japanese patent 5-44298 (JP 5-  
30 44298), which describes a pump for moving liquid. Actin is mounted onto a surface

- 4 -

of a container in the direction of the desired flow, and meromyosin and ATP are supplied in the liquid. The interaction of the meromyosin and actin "push" the liquid in the direction of flow.

5 Nicolau et al., *SPIE* 3241:36-46, 1997 discusses constructing a molecular motor or engine using actin and myosin. A rotatable gear is mounted on a stationary base, and the gear has teeth to which arms of actin are attached. Using lithographic techniques of the type used in semiconductor fabrication, a track of myosin is laid down along the peripheral edge of the stationary base so that the arms of actin on the rotatable gear can adhere to the track, and pull the teeth of the gear along the myosin track when ATP is supplied to the system. This arrangement is apparently designed to rotate the gear, and impart rotation to a driven gear that engages the driving gear. 10 However, the myosin track in such a device would be crushed by the teeth of the gear as the gear rotates, or would jam.

Moreover, precise microlithographic positioning of the actin and myosin 15 molecules would be difficult, and perhaps unfeasible, and alignment of the actin arms along the myosin track could not be maintained. It also does not appear that the molecular motor could be scaled up to macroscopic proportions, nor is it clear how the power or speed of the device could be controlled.

It is a goal of certain embodiments of the present invention to solve some 20 of the problems of prior approaches by devising a molecular motor that is more easily fabricated, and may if desired be scaled up to macroscopic proportions.

It is also a goal of some embodiments to devise such a molecular motor in which power and speed of the motor can be more conveniently controlled.

## 25 SUMMARY OF THE INVENTION

The molecular motor of the present invention includes first and second complementary two dimensional arrays of a motor protein, for example adhered to a substrate surface. The first and second arrays of motor proteins are in sufficiently close contact to interact and directionally move one array (and its attached substrate)

- 5 -

relative to the other. This action in turn moves a driven member, such as a shaft or gear, to convert the movement into useful power that can produce work.

In some embodiments, there are multiple layers of nested (for example concentric) complementary first and second arrays that interact with one another to directionally move the first and second arrays relative to one another. The arrays may be adhered to a curved surface, such as a continuous curved surface of rotation having a longitudinal axis and an internal radius (for example a cylinder or cone). Multiple concentric cylinders or nested cones (which rotate around a common central longitudinal axis) can form a series of complementary surfaces to which the arrays are adhered,

In particular embodiments, the motor proteins are actin and myosin, and the motor includes a source of ATP for activating the myosin to operate the motor. The ATP can be supplied in a liquid that flows longitudinally through the rotatable surfaces on which the arrays are adhered, or the ATP containing liquid may be infused through perforations in surfaces on which the arrays are disposed, to allow permeation of an ATP containing liquid through the surfaces to the motor proteins.

An array of the first motor protein may be coated on a first curved surface, and an array of the second motor protein may be coated on a second complementary curved surface, such that the first and second motor proteins interact to move the second surface in a predetermined direction relative to the first surface. In this example, one of the arrays is coated on an outer surface of a cylinder, shaft or cone, and another of the arrays is coated on an inner surface of a surrounding structure having a complementary shape that substantially conforms to a shape of the outer surface of the cylinder, shaft or cone. The directional movement of the second surface moves a driver, such as an internal shaft or cylinder in the motor.

Alternatively, the driver may be an outer curved surface of the motor (such as an outer surface of an outermost cylinder of the motor). The driven member can take a variety of forms, such as a rotating shaft, a propeller, a wheel, a lever-arm, a gear system, or a pulley system.

- 6 -

An advantage of the disclosed motor is that the arrays can be of a preselected dimension that provides a preselected power output of the motor. For example, the length of a cylinder on which the complementary arrays are coated can be selected to vary the power output. Alternatively, a speed of rotation of the motor can be varied by preselecting the number of multiple nested complementary arrays. Alternatively, the speed of rotation can be controlled by altering the concentration of ATP to which the motor proteins are exposed. As the concentration of ATP increases, the speed of the motor will increase up to a maximum speed, at which all the motor proteins are maximally functioning.

In a more specific embodiment, the molecular motor includes a series of concentric tubes or hollow cones, wherein each of the tubes or hollow cones has an outer surface and an inner surface. A first motor protein array (such as an actin array) is attached in a continuous ring of a selected width around the outer surface of each of the tubes or cones, and a second motor protein (such as myosin) is attached in a continuous complementary array of a corresponding width around the inner surface of each of the tubes or cones. When actin/myosin are the motor proteins, the actin is applied directionally to the surfaces, and the inner and outer surfaces are in sufficiently close contact that the motor proteins interact to move the tubes or cones relative to one another, in a direction determined by the directional application of the actin to its surface.

The motor proteins can be attached to the surfaces in a variety of ways. The actin, for example, can be expressed by recombinant techniques as a fusion protein with a histidine tag, which is then attached to a nickel-coated surface. Alternatively, the actin can be expressed with an S-tag which binds to an S-protein coated surface, or with a streptavidin tag which binds to biotin on a substrate surface. In another specific, non-limiting example, gelsolin is used to attach the actin to a surface (e.g. see Suzuki *et al.*, *Biophys. J.* 70:401-408, 1996).

In particular embodiments, the first motor protein (for example actin) is directionally attached on the outer surface of a rotatable cylinder or cone in an array that extends both longitudinally along and circumferentially around the tube or cone,

- 7 -

and the second motor protein (such as myosin) extends both longitudinally along and circumferentially around the tube or cone in a complementary array of similar size.

The invention also includes a method of making a molecular motor, by  
5 providing a first continuous curved surface which rotates around a longitudinal axis, and a second curved surface which rotates around the longitudinal axis, and is complementary in shape to the first surface. A first motor protein (such as actin) is directionally adhered to the first surface, and a second motor protein (such as myosin) is adhered to the second surface, such that the first and second motor  
10 proteins interact to move the first and second surfaces relative to one another. In particular embodiments, the actin is adhered to the surface with a tag (for example a recombinantly expressed tag such as histidine, an S-tag or streptavidin) that interacts with a component of the first surface. The actin may be directionally applied to the first curved surfaces by rotating the curved surface in an actin containing solution.

15 In certain embodiments, the motor proteins can be portions of actin and myosin that are able to function to move the surfaces relative to one another. For example, heavy meromyosin or myosin I can be used instead of myosin II. In other embodiments, the motor proteins are microtubules and kinesin, or functional fragments thereof that are sufficient to move the surfaces. The kinesin can be, for  
20 example, the N-terminal 410 amino acid residues of kinesin.

The motor of the present invention may be a micromachined device constructed on a micrometer-scale, but the motor can also be constructed on a much larger scale by coating larger surfaces with the motor proteins, which can be purified from biological tissues (such as muscle) or produced in large quantities using  
25 recombinant techniques.

The molecular motors of the present invention are believed to operate much more efficiently than conventional engines that use large temperature differentials or magnetic fields to create rotary motion with energetic efficiencies less than about 35%. The Carnot efficiency of an internal combustion engine is  
30 56%, but other losses reduce the efficiency to about 25%. Many such engines also



- 8 -

depend on fossil fuels that create air pollution and may induce global warming as a consequence of the combustion of such fuels.

Muscles use contractile or motor molecules to create macroscopic motion with efficiencies near 70%, and the molecular motors of the present invention can  
5 use similarly efficient systems to create useful energy. This can be accomplished while producing substantially no pollution, because sugar (or ATP itself) could be used to fuel the motors, and the waste products (ADP and Pi) are biologically useful or biodegradable. In addition, the isothermal conditions under which the motor operates imply low materials stress, and easier construction and maintenance.

10 The biologically compatible nature of these devices also makes them suitable for medical applications. Biologically based engines can use sugar in the blood (via substrate level phosphorylation glycolysis) as fuel, to replace neuromuscular function lost to diseases such as myasthenia gravis or muscular dystrophy. Alternatively, the motor can be used to perform the mechanical functions  
15 of a prosthetic implant.

The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description of several embodiments which proceeds with reference to the accompanying figures.

## 20 BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a schematic illustration of one embodiment of the molecular motor, in which actin is directionally applied on an outer surface of a solid internal cylinder, myosin is coated on an internal surface of a surrounding complementary hollow cylinder, and rotation of the internal cylinder drives a rotary gear. Portions  
25 of the outer cylinder are broken away to illustrate that the arrays of actin and myosin extend along the length of the device.

FIG. 2 is a schematic illustration similar to FIG. 1, but wherein the surfaces are on cones instead of cylinders.

FIG. 3A is a side elevational and FIG. 3B is a cross sectional schematic  
30 end view of an alternative embodiment of the invention in which the layer of actin

surrounds the myosin layer, the inner cylinder is fixed to a stationary bracket, and rotation of the outer cylinder rotates a propeller.

FIGS. 4A through 4D are successive schematic views illustrating a conventional view of the interaction of actin and a single myosin head, to demonstrate how an actin coated surface is moved by the myosin.

FIGS. 5A through 5E are schematic end views of cylinders similar to those shown in FIG. 1, showing a subset of myosin heads that change conformation substantially in concert to move the internal actin coated cylinder of the motor. Other myosin heads (not shown) are randomly moving through different stages of the conformational changes, without necessarily moving in concert, but only a single subset of myosin heads have been shown for purposes of explanation.

FIG. 6 is a schematic side view of an alternative embodiment of the motor having multiple, nested, concentric complementary cylinders on which the actin and myosin are coated.

FIG. 7A is a schematic end perspective view of two interengaging complementary cylinders that can be interengaged to assemble a molecular motor of the present invention.

FIG. 7B is a side view of the complementary cylinders of FIG. 4, illustrating the differing outer diameters of the two cylinders.

FIG. 8 is a schematic illustration of one embodiment of the molecular motor, in which ATP is supplied from a reservoir. Separate feed lines are used to supply the ATP to the motor. Each feed line (ATP<sub>1</sub>, ATP<sub>2</sub>, and ATP<sub>3</sub>) has a control switch or valve (designated "X" on the ATP<sub>1</sub>, ATP<sub>2</sub>, and ATP<sub>3</sub> feed lines). In one embodiment, the control valves are separately controlled.

FIG. 9 is a schematic illustration of another embodiment of the molecular motor, which includes separate units in series. In this embodiment, segments of a molecular motor, separated by impermeable barriers, are connected in series by a shaft. The barrier is designed to prevent diffusion between the molecular motor units. In this embodiment, ATP is supplied from a reservoir through separate feed lines (designated ATP<sub>1</sub>, ATP<sub>2</sub>, ATP<sub>3</sub> and ATP<sub>4</sub>). Each feed line (ATP<sub>1</sub>, ATP<sub>2</sub>, ATP<sub>3</sub>

- 10 -

and ATP<sub>4</sub>) has a separately controlled switch or valve (designated "X" on ATP<sub>1</sub>, ATP<sub>2</sub>, ATP<sub>3</sub> and ATP<sub>4</sub> feed lines).

## DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS

### 5 Definitions

The following definitions and methods are provided to better define the present invention and to guide those of ordinary skill in the art in the practice of the present invention. Definitions of common terms may also be found in Rieger *et al.*, *Glossary of Genetics: Classical and Molecular*, 5th edition, Springer-Verlag: New York, 1991; and Lewin, *Genes V*, Oxford University Press: New York, 1994. The standard one and three letter nomenclature for amino acid residues is used (such as H or His for Histidine).

Additional definitions of terms commonly used in molecular genetics can be found in Benjamin Lewin, *Genes V* published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a motor comprising "a cylinder" includes a system containing one or more cylinders, and reference to "a motor protein" includes reference to one or more motor proteins.

**Micromachining, micromachined**, and similar terms refer to the processes used to create micrometer-sized structures with primarily mechanical functions on substrates such as glass, silicon, silica, or a photoreactive polymer-coated chip.

**Motor protein** means a protein that transduces chemical energy into mechanical force and motion. Such motor proteins often exist in complementary pairs, such as actin and myosin, or kinesin and microtubules. Particular disclosed

- 11 -

motor proteins are actin/myosin and kinesin/microtubules. The motor proteins can be used in any form that is capable of transducing the chemical energy (such as the energy of ATP) into mechanical force and motion. Hence variants or fragments of the molecules can be used, such as myosin I or myosin II, or heavy meromyosin  
5 (although light meromyosin would not be suitable because it lacks the heads which change conformation to transduce the chemical energy). Similarly, variant or mutant forms of the motor proteins, such as variant actin or myosin (for example proteins in which conservative amino acid substitutions have been made) are also included, as long as they retain the motor activity. Actin is a directionally oriented  
10 molecule, that (when applied directionally to a substrate) helps direct myosin along a substrate in a direction determined by the orientation of the actin molecules on the surface. Actin and myosin have been well studied, and mutations that affect their function have been reported in the scientific literature to provide guidance about making mutants. See, for example, J. Cell. Biol., 134:895-909, 1996; J. Biol. Chem.  
15 269:18773-18780, 1994; and Bioessays 19:561-569, 1997.

The motor proteins may also include kinesin and related proteins, such as ncd, as disclosed in Endow et al., Nature 345:81-83, 1990, that are highly processive, i.e. which do not readily detach from directional microtubule tracks to which they are coupled. Once such highly processive motor proteins attach to a  
20 microtubule, there is a relatively high likelihood that they will move for many micrometers along the microtubule before becoming detached. Kinesin moves toward the plus-end of microtubules, whereas ncd moves toward the minus-end of microtubules. Hence, like actin, the microtubules can be applied directionally to a substrate to pre-select a direction of rotation of the surfaces relative to one another.  
25 The direction of rotation can be varied, depending on the complementary motor protein which is selected (for example, kinesin or ncd).

The motor proteins also include species variations, and various sequence polymorphisms that exist, wherein amino acid substitutions in the protein sequence do not affect the essential functions of the protein.

- 12 -

Coupling of a motor protein to the surfaces of the rotatable cylinders or cones of the motor can be accomplished by any method known in the art, as long as the motor activity of the protein is preserved. An example of a method of expressing actin as a fusion protein that is then coupled to a substrate is given in Example 4, in which a fusion protein is expressed by recombinant DNA technology. Briefly, a gene encoding a motor protein is operably linked to a gene encoding a selected tag (such as poly-His or streptavidin) to construct a gene fusion, which is then expressed in a suitable expression system such as *E. coli* or yeast to produce the fusion protein. Coupling of the motor protein to the substrate can also be accomplished by other methods, such as chemical coupling or purified proteins.

**Effective amount** means an amount of a source of chemical energy, such as ATP, sufficient to permit a selected motor protein to generate mechanical force.

**ATP** means adenosine triphosphate, a mononucleotide that stores chemical energy that is used by motor proteins, such as myosin and kinesin, for producing movement. **ADP** refers to adenosine diphosphosphate.

**GTP** means guanosine 5'-triphosphate, a mononucleotide that stores chemical energy.

**cDNA (complementary DNA):** a piece of DNA lacking internal, non-coding segments (introns) and regulatory sequences which determine transcription. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.

**Deletion:** the removal of a sequence of DNA, the regions on either side being joined together.

**Fuel source** means a molecule that stores chemical energy. In one embodiment, the energy molecule is a nucleoside triphosphate (NTP), such as ATP or GTP.

**Motor protein gene:** a gene (DNA sequence) encoding a motor protein (such as actin or myosin). A mutation of the gene (to produce variant forms of the motor protein) may include nucleotide sequence changes, additions or deletions. The term "gene" is understood to include the various sequence polymorphisms and

- 13 -

allelic variations that exist within the population. This term relates primarily to an isolated coding sequence, but can also include some or all of the flanking regulatory elements and/or intron sequences.

**NTP** means a nucleoside 5'-triphosphate, e.g. ATP or GTP.

5       **Isolated:** requires that the material be removed from its original environment. For example, a naturally occurring DNA or protein molecule present in a living animal is not isolated, but the same DNA or protein molecule, separated from some or all of the coexisting materials in the natural system, is isolated.

10       **Operably linked:** A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in  
15       the same reading frame.

**ORF:** open reading frame. Contains a series of nucleotide triplets (codons) coding for amino acids without any termination codons. These sequences are usually translatable into protein.

20       **PCR:** polymerase chain reaction. Describes a technique in which cycles of denaturation, annealing with primer, and then extension with DNA polymerase are used to amplify the number of copies of a target DNA sequence.

**Purified:** the term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified protein preparation is one in which the protein referred to is more pure than the protein in its natural  
25       environment within a cell. The term "substantially pure" refers to a purified protein having a purity of at least about 75%, for example 85%, 95% or 98%.

**Recombinant:** A recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often  
30       accomplished by chemical synthesis or, more commonly, by the artificial

- 14 -

manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.

**Sequence identity:** the similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar are the two sequences.

Methods of alignment of sequences for comparison are well-known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, *Adv. Appl. Math.* 2:482, 1981; Needleman and Wunsch, *J. Mol. Bio.* 48:443, 1970; Pearson and Lipman, *Methods in Mol. Biol.* 24: 307-31, 1988; Higgins and Sharp, *Gene* 73:237-44, 1988; Higgins and Sharp, *CABIOS* 5:151-3, 1989; Corpet et al., *Nuc. Acids Res.* 16:10881-90, 1988; Huang et al., *Comp. Appl. BioSci.* 8:155-65, 1992; and Pearson et al., *Meth. Mol. Biol.* 24:307-31, 1994.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., *J. Mol. Biol.* 215:403-10, 1990) is available from several sources, including the National Center for Biological Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. It can be accessed at <http://www.ncbi.nlm.nih.gov/BLAST/>. A description of how to determine sequence identity using this program is available at [http://www.ncbi.nlm.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nlm.nih.gov/BLAST/blast_help.html).

Variants or homologs of the motor protein are typically characterized by possession of at least 70% sequence identity counted over the full length alignment with the disclosed amino acid sequence using the NCBI Blast 2.0, gapped blastp set to default parameters. Such homologous peptides will more preferably possess at least 75%, more preferably at least 80% and still more preferably at least 90%, 95% or 98% sequence identity determined by this method. Sequence identity can be determined, in one instance, by aligning sequences and determining how many differences there are in the aligned sequence, and expressing these differences as a percentage. When less than the entire sequence is being compared for sequence identity, homologs will

- 15 -

possess at least 75% and more preferably at least 85% and more preferably still at least 90%, 95% or 98% sequence identity over short windows of 10-20 amino acids.

Methods for determining sequence identity over sequence windows are described at [http://www.ncbi.nlm.nih.gov/BLAST/blast\\_FAQs.html](http://www.ncbi.nlm.nih.gov/BLAST/blast_FAQs.html). For comparisons of nucleic acid sequences of less than about 150 nucleic acids, the Blast 2 sequences function is employed using the default 0 BLOSUM62 matrix set to default parameters, (OPEN GAP 5, extension gap 2). Nucleic acid sequences with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 45%, 50%, 70%, 80%, 85%, 90%, 95% or 98% sequence

identity.

The present invention provides not only the peptide homologs that are described above, but also nucleic acid molecules that encode such homologs.

**Transformed:** A transformed cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. As used herein, the term transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

**Vector:** A nucleic acid molecule is introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art.

## Particular Embodiments

### EXAMPLE 1

A particular embodiment of the molecular motor 10 is illustrated in FIG. 1, in which the motor is shown to include a solid inner cylinder 12 and a hollow outer cylinder 14 that is of slightly larger diameter than inner cylinder 12. An extension 16 of inner cylinder 12 projects from motor 10, and carries a driver in the



- 16 -

form of a toothed gear 18. The teeth on gear 18 mesh with the teeth of a larger gear 20, so that rotation of gear 18 in the direction of arrow 22 will rotate gear 20 in the direction of arrow 24.

Although the dimensions of motor 10 are not critical, the inner cylinder  
5 12 may have a diameter of 20 microns to 1 meter, for example 1 cm, while the outer cylinder 14 may have a diameter of 40 microns to 1 meter, for example 1 cm. A clearance distance between an outer surface of cylinder 12 and an inner surface of cylinder 14 is, for example, in the range of 20 to 30 microns.

Referring again to FIG. 1, a layer of actin 30 is directionally applied to  
10 the outer surface of cylinder 12, with the directional orientation shown as arrows in the drawing. As described in greater detail in Example 4, the actin protein may be expressed with a histidine tag (for example His-6) that binds to nickel. The actin is polymerized to form actin fibers by bringing a  $Mg^{2+}$  concentration to physiological levels, as described in Korn et al., *Science* 238:638-644, 1987. A cylinder with a  
15 nickel outer surface is placed into the actin-His-6 fiber solution so that the fibers attach to the surface of the cylinder. The cylinder may then be placed in a normal (non-His-6) actin solution (for example by adding normal actin to the solution) to extend the actin fibers to a length beyond their persistence length (at which point the actin has no particular direction). More actin-His-6 is then added to the solution, so  
20 that the ends of the actin cables have a His tag, and the cylinder is rotated in the actin solution to directionally orient the actin cables, and allow the His tags at the free end of the actin cables to attach to the nickel containing surface of the cylinder 12.

The directionality of the actin cables is schematically illustrated in FIG. 1  
25 by arrows 32 in the actin layer 30. As shown by the cut away portion of cylinder 14 in FIG. 1, the coating of actin covers the curved surface of inner cylinder 12 substantially along its length, for substantially coating that surface of the cylinder. In particular embodiments, the actin is present in a substantially continuous layer around the circumference of the cylinder 12, for substantially the entire length of the  
30 cylinder inside outer cylinder 14. The thickness of the actin layer may be, for

- 17 -

example, 1 to 10 molecules thick, and in a particular disclosed embodiment is one molecule thick.

The myosin (for example in the form of myosin I, myosin II, or heavy meromyosin, or variants thereof) can be adhered to the inner surface of cylinder 14, before actin coated cylinder 12 is placed inside cylinder 14. The myosin is adhered to the inner surface of cylinder 14 by adhesion, or by the techniques shown in *Finer et al.*, *Nature* 368:113-119, 1994, and *Ishijima et al.*, *Cell* 92:161-171, 1998, as well as *Ishijima et al.*, *Biophys. J.* 70:383-400, 1996 (incorporated by reference), in which myosin was purified and bound to a glass surface. When heavy meromyosin (HMM) is used as the motor protein, the technique used in *Suzuki et al.*, *Biophys. J.* 72:1997-2001, 1997 (incorporated by reference) can be used. In this method, HMM (0.1 mg/ml) in an assay buffer solution (40 mM KCl, 3 mM MgCl<sub>2</sub>, 2mM EGTA, 10 mM dithiothreitol, and 20 mM HEPES at pH 7.8) is dropped on to a polymethylmethacrylate (PMMA) substrate, and the HMM is adsorbed. PMMA is a useful substrate, because photolithographic patterns can be made in them, if desired, and the HMM placed into the tracks. In FIG. 1, the myosin is schematically shown as myosin heads 34 projecting from the inner surface of cylinder 14.

Once the myosin has been adhered to the inner surface of cylinder 14, cylinder 12 may be inserted inside cylinder 14, with both cylinders arranged concentrically around a common longitudinal axis 36. External cylinder 14 may be mounted to a stationary surface 38 by a bracket 40, so that the cylinder 14 remains fixed, and inner cylinder 12 is free to rotate relative to cylinder 14, around the central longitudinal axis 36.

In operation, a solution that contains an effective concentration of ATP is introduced into the flow space 42 between cylinders 12, 14, and allowed to flow through the cylinders along their entire length. Particular concentrations of ATP (Sigma Chemical Co., St. Louis, MO.) that can be supplied are solutions with an ATP concentration of 0.1 to 1000  $\mu$ M, for example 1  $\mu$ M. Greater concentrations of ATP would activate more of the myosin molecules, and increase the speed of the motor, by rotating cylinder 12 relative to cylinder 14. As cylinder 12 rotates,

- 18 -

extension 16 rotates gear 18 in the direction of arrow 22, which in turn rotates gear 20 in the direction of arrow 24. The molecular mechanism by which this rotation is achieved is described in more detail in Example 2.

An alternative embodiment is shown in FIG. 2, which is similar to that shown in FIG. 1, such that like parts have been given like reference numbers plus 100. However, instead of inner and outer cylinders, the motor includes inner and outer frusto-cones 112, 114 (which for simplicity will be referred to as "cones" 112, 114). FIG. 2 shows the molecular motor 110 in which the outer cone 114 is mounted to a bracket 140 and surface 138. Outer cone 114 is positioned around inner cone 112, such that the cones taper in a complementary fashion, from a large diameter base to a smaller diameter tip, and rotate around a common longitudinal axis of rotation 136. A layer of actin 130 is directionally attached to the outer surface of inner cone 112, while myosin 134 is adhered to the inner surface of outer cone 114. When supplied with fuel, inner cone 112 rotates extension 116 and driving gear 118 in the direction of arrow 122, which in turn rotates driven gear 120 in the direction of arrow 124.

An advantage of the embodiment of FIG. 2 is that the motor can be assembled by inserting inner cone 112 inside outer cone 114, with less shearing force than may be encountered when introducing an inner cylinder into a larger outer cylinder. Since the smaller diameter top portion of the tapering inner cone 112 can be introduced into the larger diameter base opening of the outer tapering cone 114, there is a greater clearance between the inserted end and the surrounding cone than would occur with two cylinders, each of which has a constant radius. As the inner cone 112 is progressively inserted into the outer cone 114, the minimum desired operational clearance between the actin and myosin layers is not reached until the two cones reach their final operational positions. Hence the opportunity for shearing of the actin and myosin layers, by frictional forces encountered as the motor is assembled, is minimized.

Another alternative embodiment of the motor is shown in FIGS. 3A and 3B, in which a hollow inner cylinder 43 is surrounded by an outer cylinder 44.

- 19 -

Myosin 45 (with the heads shown in random states of conformational change in FIG. 3B) is coated on an external surface of inner cylinder 43, while a layer of actin 46 is directionally applied to an inner surface of outer cylinder 44. Openings 47 are arrayed circumferentially around outer cylinder 44, and provide passageways through the cylinder 44 and actin layer 46, through which an ATP containing liquid can be introduced into the space between cylinders 43 and 44. Inner cylinder 43 extends beyond an open end of outer cylinder 44, and is mounted on a stationary bracket 48. Myosin need not be coated on the outer surface of cylinder 43 which extends out of cylinder 44.

In operation, a liquid containing a sufficient concentration of ATP is introduced through passageways 47, for example through manifold tubes (not shown) which communicate with the passageways. In the presence of the ATP, the myosin heads 45 undergo a conformational change to attach to actin layer 46 and move it in the direction indicated by arrow 49. As the actin layer is moved, its attached outer cylinder 44 is rotated around its longitudinal axis in the direction 49, which in turn rotates propeller blades 51 that extend outwardly from the outer surface of cylinder 44. The rotation of blades 51 can be converted to useful work, such as the generation of power.

Although FIGS. 3A and 3B show perforations 47 in the external cylinder 44 for introducing liquid fuel into the motor, the liquid could similarly be introduced into the interior of the hollow inner cylinder 43. Perforations in cylinder 43 could be provided to direct the flow of liquid out of the inner cylinder, and this flow would be encouraged by rotation of the surrounding outer cylinder 44.

The molecular motor can be used in a biological organism, such as a mammal, for example to move limbs or other body parts that may have lost neuromuscular activity. When used to move a limb, for example, the rotation of outer cylinder 44 can be used to rotate a joint, for example to perform pronation or supination of the forearm. In an assembly such as that shown in FIGS. 3A and 3B, the inner cylinder can be fixed axially to a bone (such as the radius or ulna, or both), and the rotating outer cylinder can be fixed to the humerus. Activation of the motor

- 20 -

would then rotate the forearm relative to the upper arm. In such an example, a motor with multiple layers would likely be required to provide sufficient power to rotate a joint.

In yet other applications, the molecular motor may be used in a robot, for example to rotate joints of the extremities or trunk. Rotation of the motor can also be used in a pump to propel fluids. Very large versions of the motor (such as multiple cylinder embodiments about one meter wide) could also be used in automobiles to replace conventional internal combustion motors.

## EXAMPLE 2

### Movement of Substrates by Conformational Change of Myosin Heads

The molecular mechanism by which conformational changes of the myosin heads move an actin coated substrate are illustrated in FIGS. 4 and 5, which depict a conventional version of the mechanism of muscle contraction. Although this version is illustrated for purposes of explanation and illustration, the invention is not limited to this theory, and covers any actual mechanism of muscle contraction eventually discovered.

FIG. 4 shows a flat substrate 200 coated with a directionally oriented layer of actin 202. In FIG. 4A, the myosin head 204 is shown at the end of a power stroke which has moved substrate 200. In step 1 between FIG. 4A and FIG. 4B, ATP binds to the myosin head 204, which causes release of the myosin head 204 from the actin 202. ATP is then rapidly hydrolyzed, leaving ADP and inorganic phosphate (P<sub>i</sub>) bound to the myosin 204, and resulting in a conformational change (FIG. 4C) in the shape of the myosin head which moves the head backward with respect to the direction of desired movement of the actin. This change is followed by the myosin binding to actin in a high energy state (FIG. 4D). The ADP-P<sub>i</sub> is then released, which results in another conformational change that moves the myosin in the direction of arrow 206, and drives the actin filament by a distance of between 4 and 10 nm in that direction.

- 21 -

A similar proposed mechanism applies to the movement of a curved substrate, such as the cylinder 212 (FIG. 5) which is coated with the layer of actin 230. FIG. 5A shows the myosin heads 234 at the end of a power stroke. Although several myosin heads are shown in FIG. 5 undergoing uniform movements, the myosin head which are shown are only a subset of myosin molecules that are undergoing similar conformational changes. Although not shown in the drawing, many other myosin molecules are simultaneously in different stages of the cycle.

In step 1, between FIGS. 5A and 5B, ATP binds to the myosin heads 234, which causes release of the heads from the directionally oriented actin layer 230. The ATP is subsequently hydrolyzed in step 2, leaving ADP and Pi (illustrated as a black spot on the myosin head in FIG. 5C), and resulting in a conformational change that moves the myosin head in a direction opposite the direction of movement of the directionally oriented actin. The myosin heads then attach to the actin fibers (FIG. 5D), and the ADP-Pi is released, resulting in a conformational change of the myosin that drives the heads in the direction of arrow 236. This movement in turn moves the actin in the direction of arrow 236 to turn the inner cylinder, and power the motor.

### EXAMPLE 3

#### Multiple Concentric Cylinders to Increase Speed of Motor

Another embodiment of the motor is shown in FIG. 6, in which multiple concentric cylinders are used to construct a motor that can rotate at a higher speed than a motor having only an inner and an outer cylinder. In the embodiment of FIG. 6, the motor includes a solid inner cylinder 270, an intermediate cylinder 272, and an outer cylinder 274. Although three cylinders are shown in this example, a motor containing many more cylinders (for example 5, 10, 25, 50 or even more concentric cylinders) can similarly be used.

The construction of the motor in FIG. 6 is analogous to that shown in FIGS. 1-3, in that opposing surfaces of the cylinders are coated with complementary pairs of motor proteins, such as actin and myosin. Hence inner cylinder 270 has a

- 22 -

layer of actin 276a directionally coated on its external surface, while intermediate cylinder 272 has a coating of myosin 278a on its inner surface. Intermediate cylinder 272 also has a directional layer of actin 276b on its outer surface, and outer cylinder 274 has a coating of myosin 278b on its inner surface.

5 In operation, the outer cylinder 274 is held stationary, for example by a bracket. When an ATP-containing liquid is introduced into the spaces between the three cylinders, the myosin on the inner surface of outer cylinder 274 moves intermediate cylinder 272 in the direction indicated by arrow 280. Simultaneously the inner cylinder 270 is rotated in the direction of arrow 280 by the interaction of  
10 the complementary actin and myosin layers on the cylinders 270, 272. Hence the rotational speed of inner cylinder 270 is the sum of the rotational speeds of intermediate cylinder 272 and inner cylinder 270. By using even more concentric cylinders that rotate about a common longitudinal axis, the rotational speed on the inner cylinder can be increased correspondingly.

15 Alternatively, in embodiments such as that shown in FIGS. 3A and 3B in which the outer cylinder rotates relative to a stationary inner cylinder, multiple concentric cylinders in the motor would increase the rotational speed of the external cylinder.

FIGS. 7A and 7B illustrate a particular mode of assembly of molecular  
20 motors that have multiple concentric nested cylinders. A first set 281 of hollow coaxial cylinders is held in the concentric array shown in FIG. 7A, for example by a series of internal struts, or by affixation of an external end plate 280 (FIG. 7B) at a closed end of the array. Set 281 includes three hollow coaxial cylinders, consisting of an inner cylinder 282, and intermediate cylinder 284, and an outer cylinder 286.  
25 A second set 287 of coaxial cylinders is similarly held in a concentric array by internal struts, or affixation of an external end plate 283 at a closed end of the array (FIG. 7B). Set 287 also includes three cylinders, consisting of an inner cylinder 288, an intermediate cylinder 292, and an outer cylinder 290.

The overall outer diameter R1 of set 281 is slightly less than an overall  
30 outer diameter R2 of set 287, and the corresponding arrays of the alternate sets 281,

- 23 -

287 have staggered diameters from the innermost to the outermost cylinder. Hence the outer diameter of cylinder 282 is slightly less than the inner diameter of cylinder 288. Similarly, the outer diameter of cylinder 288 is slightly less than the inner diameter of cylinder 284, and the outer diameter of cylinder 284 is slightly less than the inner diameter of cylinder 292.

As illustrated schematically in FIG. 7A, actin is directionally applied to the outer surfaces of both of the cylinders 282, 284 (where the directional application of the actin is illustrated by the direction of the arrows on the outer surfaces of those cylinders). Myosin is applied to the inner surfaces of cylinders 288, 290, and 292. Hence the motor can be assembled by introducing set 281 into set 287, so that the cylinders of set 281 interdigitate with the cylinders of set 287. Once assembled, the motor can be operated by introducing an ATP containing liquid into the spaces between the cylinders.

In another embodiment (not shown), each actin bearing surface can have raised circumferential ridges longitudinally spaced along it. Such raised ridges would provide areas of reduced clearance between the inner and outer cylinders, to increase the interaction between the cylinders.

When a set number of concentric nested cylinders is included in a molecular motor, the motor operates at a defined maximum power and speed. However, it may be desirable to be able to vary the power of the motor. As shown in FIG. 8, the molecular motor may be elongated along the horizontal axis. The fuel source (e.g., an energy molecule such as a nucleotide triphosphate, NTP) is provided from a reservoir. In one embodiment, the fuel source ATP.

The fuel source is selected based on the enzyme system of the molecular motor. For example, if helicases and DNA strands are included in a molecular motor, NTPs are provided in the reservoir (see Waksman et al., Nat. Struct. Biol. 7:20-22, 2000 for a discussion of helicases). In another specific, non-limiting example, actin and myosin are included in the molecular motor, and ATP is provided as the fuel source in the reservoir.



- 24 -

The fuel source (e.g. ATP) is supplied to the molecular motor by feed lines (designated ATP<sub>1</sub>, ATP<sub>2</sub>, ATP<sub>3</sub>) that are controlled by switches or valves (designated X on feed lines ATP<sub>1</sub>, ATP<sub>2</sub>, ATP<sub>3</sub>) that regulate the flow rate of fuel (e.g. ATP) through the feed lines. Power is varied by changing the amount of available fuel along the length of the motor using the control switches or valves.

In the embodiment illustrated, there are three feed lines and switches, however, any number of independently controlled feed lines and switches can be utilized. The control switches or valves can be regulated individually, regulated in groups (e.g. 2, 3, or 4 valves that are regulated together), or can be regulated as a single unit.

Thus, in one specific, non-limiting example, independently controlled switches are utilized to control the flow of ATP through the feed lines. If three switches and three ATP feed lines are connected to the motor, switching one of the three independently controlled switches off decreases the power to two-thirds of the maximal power.

Another embodiment of the molecular motor, wherein power can be regulated, is shown in FIG. 9. In this embodiment, independent segments of a molecular motor are provided. Each segment of the motor (shown as an independent cylinder) is attached to one end of a feed line (designated ATP<sub>1</sub>, ATP<sub>2</sub>, ATP<sub>3</sub> and ATP<sub>4</sub>). The other end of each feed line is connected to a fuel source (e.g. ATP) in a reservoir, which can deliver the fuel through the feed lines to the segments of the molecular motor. In the embodiment shown, the flow of ATP from the reservoir through the feed lines is controlled by valves or switches (designated "X" on each feed line). The motor segments are separated by impermeable barriers (shown schematically as squares) that prevent, or substantially inhibit, diffusion between the motor segments.

In the embodiment illustrated, four feed lines and switches are shown, however, any number of independently controlled feed lines and switches can be utilized. Moreover, each of the segments can have multiple supply lines (as in FIG. 8). The control switches or valves shown in FIG. 9 can be regulated individually,

- 25 -

regulated in groups (e.g. 2, 3, or 4 valves that are regulated together), or can be regulated as a single unit.

In one specific, non-limiting example, segments of the motor are powered independently to avoid shear. For example, if the segments are numbered sequentially, the switch can be used to prevent delivery of ATP to every other segment (e.g. the odd segments) in order to run the molecular motor at half of the maximum power. Similarly, the switch can be used to prevent delivery of ATP to every third segment (e.g. those with a multiple of three) to run the molecular motor at two-thirds power. The switch can also be used to prevent delivery of ATP to two out of three segments to run the molecular motor at one-third power.

The segments of the motor can all be of the same length, or can have different lengths. Altering the lengths of the segments allows variations in power. In addition, altering the numbers of nested cylinders allows the velocity to be varied. Thus, a range of controls is provided.

In one embodiment, a series in which the first segment has a unit length of 1, a second segment has a unit of length 2, and third segment has a unit of length of 4, and a fourth segment has a unit length of 8 is provided. This series can, by binary combinations, be programmed to have from 0 to 15 units of power. One of skill of the art will be able to determine an appropriate switching paradigm of segments of molecular motor of various lengths such that any desired fraction of the maximal power of the molecular motor can be achieved.

#### EXAMPLE 4

##### Preparation of Recombinant Actin

This example describes how to prepare recombinant actin molecules, which may also contain at least one affinity tag. Such tags serve as a means by which to attach actin to a substrate, and aid in the purification of recombinant actin. Purified recombinant actin may be used for the molecular motor of the present invention.

- 26 -

Standard molecular biology protocols are used for the expression and purification of recombinant actin unless otherwise stated. Such methods are described, for example, in Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York, 1989), Ausubel et al. (*Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley-Intersciences, 1987),  
5 and Innis et al., (*PCR Protocols, A Guide to Methods and Applications*, Innis et al. (eds.), Academic Press, Inc., San Diego, California, 1990).

Partial or full-length cDNA sequences, which encode for actin, may be ligated into bacterial expression vectors. The actin cDNA can be from any organism  
10 including human, chicken or mouse, and includes wild-type, mutant, and sequence variants thereof. In addition, the actin cDNA may be from any isotype of actin, including the  $\alpha$ ,  $\beta$ , and  $\gamma$  isoforms. Any sequence variants used in the present invention will retain the ability to interact with myosin so that the myosin can move the actin, as in muscle. Several actin cDNA sequences are publicly available on  
15 GenBank at: <http://www.ncbi.nlm.nih.gov/Entrez/>. Examples include the human (Accession No. J0068) and chicken (Accession Nos. V01507 J00805 K02172 K02257)  $\alpha$ -actin genes, the mouse  $\beta$ -actin gene (Accession No. X03672), and the human  $\gamma$ -actin gene (Accession Nos. X04098, K00791, M24241). It is appreciated that for mutant or variant DNA sequences, similar systems as described below are  
20 employed to express and produce the mutant or variant product.

DNA sequences can be manipulated with standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence-alteration via single-stranded bacteriophage  
25 intermediate, or with the use of specific oligonucleotides in combination with PCR. The host cell, which may be transfected with the vector of this invention, may be selected from the group consisting of bacteria, yeast, fungi, plant, insect, mouse or other animal, or human tissue cells.

The purification of recombinant fusion proteins has been made  
30 significantly easier by the use of affinity tags that can be genetically engineered at

- 27 -

either the N- or C-terminus of recombinant proteins. Such tags can be attached to actin, to aid in its purification and subsequent attachment to a substrate (see Example 1). Examples of affinity tags include histidine (His), streptavidin, S-tag, and glutathione-S-transferase (GST). Other affinity tags known to those skilled in the art may also be used.

In general, the affinity tags are placed at the N- or C-terminus of a protein. Vectors containing one or multiple affinity tags are commercially available. To prepare a Tag-actin recombinant fusion protein, vectors are constructed which contain nucleotide sequences encoding the tag, and the actin cDNA. This vector may be expressed in bacteria such as *E. coli*, and the protein purified. The method of purification will depend on the affinity tag attached. Typically, the bacterial lysate is applied to a column containing a resin having high affinity for the tag on the fusion protein. After applying the lysate and allowing the tagged-fusion protein to bind, unbound proteins (non-tagged) are washed away, and the fusion protein (containing the affinity tag) is eluted.

One of the most widely used tags contains six or ten consecutive histidine (His) residues, which has high affinity for metal ions (such as nickel ion) which can be placed on a surface of a curved substrate to which the actin is to be attached. A His-6 or His-10 moiety can be attached to actin using pET vectors (Novagen, Madison, WI). The His-actin fusion protein can be purified as described in Paborsky *et al.* (*Anal. Biochem.*, 234:60-65, 1996), herein incorporated by reference. Briefly, the cell lysate is immobilized by affinity chromatography on  $\text{Ni}^{2+}$ -NTA-Agarose (QIAGEN, Valencia, CA). After washing away unbound proteins, for example using a buffer containing 8-50 mM imidazole, 50 mM Tris HCl, pH 7.5, 150 mM NaCl, the bound recombinant protein is eluted using the same buffer containing a higher concentration of imidazole, for example 100-500 mM imidazole.

The S-tag system is based on the interaction of the 15 amino acid S-tag peptide with the S-protein derived from pancreatic ribonuclease A. Several vectors for generating S-tag fusion proteins, as well as kits for the purification of S-tagged

- 28 -

proteins, are available from Novagen (Madison, WI). For example vectors pET29a-c and pET30a-c can be used. The S-tag-actin fusion protein may be purified by incubating the cell lysate with S-protein agarose, which retains S-tag-actin fusion proteins. After washing away unbound proteins, the fusion protein is released by  
5 incubation of the agarose beads with site-specific protease, which leaves behind the S-tag peptide. The S-tagged protein can then be attached to the cylinder substrate, for example by the His tag provided by this vector on the C terminus.

The affinity tag streptavidin binds with very high affinity to biotin. Vectors for generating streptavidin-actin fusion proteins, and methods for purifying  
10 these proteins, are described in Santo and Cantor (*Biochem. Biophys. Res. Commun.* 176:571-577, 1991, herein incorporated by reference). To purify the streptavidin-actin fusion protein, the cell lysate is applied to a 2-iminobiotin agarose column (other biotin-containing columns may be used), and after washing away unbound proteins, the fusion protein is eluted. Biotin can be attached to the substrate (a  
15 surface of the cylinder, such as a glass cylinder) using the techniques disclosed by Mazzola and Fodor, *Biophys. J.* 68:1653-1660, 1995, which is incorporated by reference.

The enzyme glutathione-S-transferase (GST) has high affinity for glutathione. Plasmid expression vectors containing GST (pGEX) are disclosed in  
20 U.S. Patent No. 5,654,176 to Smith, herein incorporated by reference and in Sharrocks (*Gene*, 138:105-8, 1994, herein incorporated by reference). pGEX vectors are available from Amersham Pharmacia Biotech (Piscataway, NJ). The cell lysate is incubated with glutathione-agarose beads and after washing, the fusion protein is eluted, for example, with 50 mM Tris-HCl (pH 8.0) containing 5 mM reduced  
25 glutathione. If the GST-fusion protein is insoluble, it can be purified by affinity chromatography if the protein is solubilized in a solubilizing agent which does not disrupt binding to glutathione-agarose, such as 1% Triton X-100, 1% Tween 20, 10 mM dithiothreitol or 0.03% NaDodSO<sub>4</sub>. Other methods used to solubilize GST-fusion proteins are described by Frangioni and Neel (*Anal. Biochem.* 210:179-87,  
30 1993, herein incorporated by reference). Glutathione fusion proteins can be

- 29 -

attached to an agarose covered substrate, for example a layer of agarose on the cylindrical substrate, for example by using the techniques disclosed in Lewis et al., Protein Expr. Purif. 13:120-126, 1998, which is incorporated by reference.

5 Methods and plasmid vectors for producing fusion proteins and intact native proteins in bacteria are described in Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York, 1989, chapter 17, herein incorporated by reference). Such recombinant fusion proteins may be made in large amounts, and are easy to purify. Native proteins can be produced in bacteria by placing a strong, regulated promoter and an efficient ribosome binding site upstream  
10 of the cloned gene. If low levels of protein are produced, additional steps may be taken to increase protein production; if high levels of protein are produced, purification is relatively easy. Suitable methods are presented in Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York, 1989) and are well known in the art. Often, proteins expressed at high levels are found in  
15 insoluble inclusion bodies. Methods for extracting proteins from these aggregates are described by Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York, Chapter 17, 1989).

Vector systems suitable for the expression of actin fusion genes include the pUR series of vectors (Ruther and Muller-Hill, *EMBO J.* 2:1791, 1983), pEX1-3  
20 (Stanley and Luzio, *EMBO J.* 3:1429, 1984) and pMR100 (Gray et al., *Proc. Natl. Acad. Sci. USA* 79:6598, 1982). Vectors suitable for the production of intact native proteins include pKC30 (Shimatake and Rosenberg, *Nature* 292:128, 1981), pKK177-3 (Amann and Brosius, *Gene* 40:183, 1985) and pET-3 (Studier and Moffatt, *J. Mol. Biol.* 189:113, 1986). Actin fusion proteins may be isolated from  
25 protein gels, for use in the molecular motor. The DNA sequence can also be transferred to other cloning vehicles, such as other plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs) (Burke et al., *Science* 236:806-812, 1987). These vectors may then be introduced into a variety of hosts including somatic cells, and simple or complex organisms, such as bacteria,  
30 fungi (Timberlake and Marshall, *Science* 244:1313-1317, 1989), invertebrates,

- 30 -

plants (Gasser and Fraley, *Science* 244:1293, 1989), and mammals (Pursel et al., *Science* 244:1281-1288, 1989), which cell or organisms are rendered transgenic by the introduction of the heterologous actin cDNA.

For expression in mammalian cells, the actin cDNA sequence may be  
5 ligated to heterologous promoters, such as the simian virus SV40 promoter, in the pSV2 vector (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981), and introduced into cells, such as monkey COS-1 cells (Gluzman, *Cell* 23:175-82, 1981), to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical  
10 selection, such as neomycin (Southern and Berg, *J. Mol. Appl. Genet.* 1:327-41, 1982) and mycophenolic acid (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981).

The cDNA sequence (or portions derived from it) or a mini gene (a cDNA with an intron and its own promoter) may be introduced into eukaryotic  
15 expression vectors by conventional techniques. These vectors are designed to permit the transcription of the cDNA eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation. Vectors containing the promoter and enhancer regions of the SV40 or long terminal repeat (LTR) of the Rous Sarcoma virus and polyadenylation  
20 and splicing signal from SV40 are readily available (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981; Gorman et al., *Proc. Natl. Acad. Sci. USA* 78:6777-6781, 1982). The level of expression of the cDNA can be manipulated with this type of vector, either by using promoters that have different activities (for example, the baculovirus pAC373 can express cDNAs at high levels in *S. frugiperda*  
25 cells (Summers and Smith, *Genetically Altered Viruses and the Environment*, Fields et al. (Eds.) 22:319-328, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1985) or by using vectors that contain promoters amenable to modulation, for example, the glucocorticoid-responsive promoter from the mouse mammary tumor virus (Lee et al., *Nature* 294:228, 1982). The expression of the

- 31 -

actin cDNA can be monitored in the recipient cells 24 to 72 hours after introduction (transient expression).

In addition, some vectors contain selectable markers such as the *gpt* (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-6, 1981) or *neo* (Southern and Berg, *J. Mol. Appl. Genet.* 1:327-41, 1982) bacterial genes. These selectable  
5 markers permit selection of transfected cells that exhibit stable, long-term expression of the vectors (and therefore the cDNA). The vectors can be maintained in the cells as episomal, freely replicating entities by using regulatory elements of viruses such as papilloma (Sarver et al., *Mol. Cell Biol.* 1:486, 1981) or Epstein-Barr (Sugden et al., *Mol. Cell Biol.* 5:410, 1985). Alternatively, one can also produce cell lines that  
10 have integrated the vector into genomic DNA. Both of these types of cell lines produce the gene product on a continuous basis. One can also produce cell lines that have amplified the number of copies of the vector (and therefore of the cDNA as well) to create cell lines that can produce high levels of the gene product (Alt et al.,  
15 *J. Biol. Chem.* 253:1357, 1978).

The transfer of DNA into eukaryotic, in particular human or other mammalian cells, is now a conventional technique. The vectors are introduced into the recipient cells as pure DNA (transfection) by, for example, precipitation with calcium phosphate (Graham and vander Eb, *Virology* 52:466, 1973) or strontium  
20 phosphate (Brash et al., *Mol. Cell Biol.* 7:2013, 1987), electroporation (Neumann et al., *EMBO J* 1:841, 1982), lipofection (Felgner et al., *Proc. Natl. Acad. Sci. U S A.* 84:7413-7417, 1987), DEAE dextran (McCuthan et al., *J. Natl Cancer Inst.* 41:351, 1968), microinjection (Mueller et al., *Cell* 15:579, 1978), protoplast fusion (Schafner, *Proc. Natl. Acad. Sci. USA* 77:2163-7, 1980), or pellet guns (Klein et al.,  
25 *Nature* 327:70, 1987). Alternatively, the cDNA can be introduced by infection with virus vectors. Systems are developed that use, for example, retroviruses (Bernstein et al., *Gen. Engrg.* 7:235, 1985), adenoviruses (Ahmad et al., *J. Virol.* 57:267, 1986), or Herpes virus (Spaete et al., *Cell* 30:295, 1982).

Using the above techniques, the expression vectors containing the actin  
30 gene or cDNA sequence or fragments or variants or mutants thereof can be



- 32 -

introduced into human cells, mammalian cells from other species or non-mammalian cells as desired. For example, monkey COS cells (Gluzman, *Cell* 23:175-82, 1981) that produce high levels of the SV40 T antigen and permit the replication of vectors containing the SV40 origin of replication may be used. Similarly, Chinese hamster  
5 ovary (CHO), mouse NIH 3T3 fibroblasts or human fibroblasts or lymphoblasts may be used.

The recombinant cloning vector, according to this invention, then comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host. The DNA is operatively linked in the vector to an expression  
10 control sequence in the recombinant DNA molecule so that the actin polypeptide can be expressed. The expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be specifically selected from the group consisting of the lac system,  
15 the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, the promoter of the yeast alpha-mating factors and combinations  
20 thereof.

### EXAMPLE 5

#### Motor Protein Variants

Variants of the motor proteins (such as actin and myosin) can be used  
25 instead of the native proteins, as long as the variants retain the motor activity. DNA mutagenesis techniques may be used to produce variant DNA molecules, and will facilitate the production of proteins which differ in certain structural aspects from the native protein, yet the variant proteins are clearly derivative and maintain the essential functional characteristic of the motor protein as defined above. Newly  
30 derived proteins may also be selected in order to obtain variations in the

characteristics of the motor protein, as will be more fully described below. Such derivatives include those with variations in the amino acid sequence including minor deletions, additions and substitutions.

While the site for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at a target codon or region and the expressed protein variants screened for optimal activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known.

Amino acid substitutions are typically of single residues, for example 1, 2, 3, 4 or more substitutions; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. Obviously, the mutations that are made in the DNA encoding the protein must not place the sequence out of reading frame, and preferably will not create complementary regions that could produce secondary changes in the mRNA structure.

Substitutional variants are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions are generally conservative substitutions when it is desired to finely modulate the characteristics of the protein. Examples of such conservative substitutions are well known, and are shown, for example, in U.S. Patent No. 5,928,896 and U.S. Patent No. 5,917,019.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in protein properties will be those in which (a) a

- 34 -

hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histadyl, is substituted for (or by) an

5 electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

In view of the many possible embodiments to which the principles of our invention may be applied, it should be recognized that the illustrated embodiment is

10 only a particular example of the invention and should not be taken as a limitation on the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.

- 35 -

We claim:

1. A molecular motor comprising:  
a first two dimensional array of a first motor protein;  
a second two dimensional array of a second motor protein that interacts  
5 with the first motor protein to move directionally relatively to the first array; and  
wherein the first and second arrays of motor proteins are in sufficiently  
close contact to interact and move the second array relative to the first array.
2. The molecular motor of claim 1, further comprising a driven member  
moved by the directional movement of the second array.
- 10 3. The molecular motor of claim 1, further comprising multiple nested  
first and second arrays that interact with one another to directionally move the first  
and second arrays relative to one another.
4. The molecular motor of claim 1, wherein each two dimensional array  
is a curved surface.
- 15 5. The molecular motor of claim 4, wherein each curved surface is a  
continuous curved surface.
6. The molecular motor of claim 5, wherein each curved surface is a  
complementary shaped cylindrical or conical surface.
7. The molecular motor of claim 6, comprising a plurality of nested  
20 cylindrical or conical members, the surfaces thereof forming the complementary  
curved surfaces.
8. The molecular motor of claim 1, wherein the first motor protein is  
actin and the second motor protein is myosin.
9. The molecular motor of claim 1, further comprising a source of ATP.
- 25 10. The molecular motor of claim 1, further comprising perforations in  
surfaces on which the arrays are disposed, to allow permeation of an ATP containing  
liquid through the surfaces to the motor proteins.
11. The molecular motor of claim 1, wherein the first array is coated on a  
first curved surface, and the second array is coated on a second curved surface.

- 36 -

12. The molecular motor of claim 10, wherein one of the arrays is coated on an outer surface of a cylinder, shaft or cone, and another of the arrays is coated on an inner surface of a surrounding structure having a complementary shape that substantially conforms to a shape of the outer surface of the cylinder, shaft or cone.

5

13. The molecular motor of claim 1, wherein directional movement of the second array moves a driver.

14. The molecular motor of claim 13, wherein the driver is an internal shaft or cylinder in the motor.

10

15. The molecular motor of claim 13, wherein the driver is an outer curved surface of the motor.

16. The molecular motor of claim 2, wherein the driven member is a rotating shaft, a propeller, a wheel, a lever-arm, a gear system, or a pulley system.

15

17. The molecular motor of claim 1, wherein the arrays are of a preselected dimension that provides a preselected power output of the motor.

18. The molecular motor of claim 17, wherein the preselected dimension is a length of the array.

19. The molecular motor of claim 3, wherein a preselected number of multiple nested arrays are provided to select a speed of rotation of the motor.

20

20. A molecular motor, comprising:

a curved continuous first surface to which is attached a circumferential coating of a first motor protein;

25

a complementary continuous curved second surface to which is attached a circumferential coating of a second motor protein that interacts with the first motor protein to move the second surface relative to the first surface.

21. The molecular motor of claim 20, wherein the continuous curved surface is a closed surface of rotation having an internal radius.

22. The molecular motor of claim 21, wherein the closed surface of rotation is a cylindrical or conical surface.

- 37 -

23. The molecular motor of claim 20, wherein the first motor protein is actin and the second motor protein is myosin.

24. A molecular motor comprising:

5 a series of concentric tubes or hollow cones, wherein each of the tubes or hollow cones has an outer surface and an inner surface;

a first motor protein attached in a continuous ring around the outer surface of each of the tubes or cones;

a second motor protein attached in a continuous complementary ring around the inner surface of each of the tubes or cones;

10 wherein one of the motor proteins is applied directionally to the surfaces, and the inner and outer surfaces are in sufficiently close contact that the first and second motor proteins interact to move the first and second motor proteins, and the outer and inner surface, relative to one another.

25. The molecular motor of claim 24, wherein the first motor protein is actin, which is applied directionally around the outer surface of each of the tubes or cones, and the second motor protein is myosin, which interacts with the actin to move the inner surfaces relative to the outer surfaces.

26. The molecular motor of claim 25, wherein the outer surface includes nickel, and the actin is anchored to the outer surface by a histidine tag which binds to the nickel in the outer surface.

27. The molecular motor of claim 24, wherein the first motor protein is present on the outer surface in an array that extends both longitudinally along and circumferentially around the tube or cone.

28. The molecular motor of claim 24, further comprising a driver rotated by movement of the first and second motor proteins relative to one another.

29. The molecular motor of claim 28, wherein the driver is driven by a rotating inner tube or cone of the motor.

30. The molecular motor of claim 28, wherein the driver is driven by a rotating outermost tube or cone.

- 38 -

31. A molecular motor comprising:

an inner cylinder or tube, having a coating of actin directionally adhered to an outer surface of the cylinder;

5 a tubular member around the inner cylinder, the tubular member having a coating of myosin adhered to an inner surface of the tubular member, with the actin and myosin interacting to move the inner surface relative to the outer surface.

32. A method of making a molecular motor, comprising:

providing a first continuous curved surface which rotates around a longitudinal axis;

10 providing a second curved surface which rotates around the longitudinal axis, and is complementary in shape to the first surface;

adhering a first motor protein to the first surface, and adhering a second motor protein to the second surface, wherein the first and second motor proteins interact to move the first and second surfaces relative to one another.

15 33. The method of claim 32, wherein one of the motor proteins is actin and another of the motor proteins is myosin.

34. The method of claim 33, wherein the actin is adhered to the surface with a tag that interacts with a component of the surface.

20 35. The method of claim 34, wherein the actin is recombinant actin expressed with the tag.

36. The method of claim 34, wherein the tag comprises histidine, an S-tag, or streptavidin.

25 37. The method of claim 33, wherein the actin is directionally applied to one of the curved surfaces by rotating the curved surface in an actin containing solution.

38. The method of claim 32, further comprising:

supplying a fuel source to the first and second motor proteins to activate movement of the first and second surfaces relative to one another.

39. The method of claim 38, wherein the fuel source is ATP.

- 39 -

40. The molecular motor of claim 1, further comprising:  
a supply of a fuel source, wherein the supply of the fuel source is used to  
activate movement of the second array relative to the first array.



41. The molecular motor of claim 40, wherein the supply of the fuel  
5 source is a regulated supply of the fuel source.

42. The molecular motor of claim 41, wherein the regulated supply of the  
fuel source is regulated by a switch or a valve.

43. The molecular motor of claim 40, wherein the fuel source is ATP.



1/5



2/5

FIG. 3A








FIG. 3B





4/5

FIG. 6




FIG. 7A





FIG. 7B



5/5

FIG. 8





FIG. 9



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/20925

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C07K14/47 C12N11/00 B82B1/00 H02N6/00 B23Q1/56		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K B82B H02N B23Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) CHEM ABS Data, EPO-Internal, PAJ, MEDLINE, BIOSIS, INSPEC, COMPENDEX, WPI Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 761 960 A (SAITOH AKIO ET AL) 9 June 1998 (1998-06-09)	1-43
Y	column 7-9; figures 12,13 ---	26
Y,0	C. MONTEMAGNO ET AL.: "Constructiong biological motor powered nanomechanical devices" SIXTH FORESIGHT CONFERENCE ON MOLECULAR NANOTECHNOLOGY, [Online] 12 - 15 November 1998, Retrieved from the Internet: <URL:http://www.foresight.org/Conferences/ MNT6/Papers/Montemagno/index.html> [retrieved on 2000-12-13]	26
X	the whole document --- -/--	1-10
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center; font-weight: bold;">14 December 2000</div>		Date of mailing of the international search report  <div style="text-align: center; font-weight: bold;">22 12 2000</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center; font-weight: bold;">Cervigni, S</div>

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/20925

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THOMAS N ET AL: "THE PHYSICS OF BIOLOGICAL MOLECULAR MOTORS" JOURNAL OF PHYSICS D. APPLIED PHYSICS, IOP PUBLISHING, BRISTOL, GB, vol. 31, no. 3, 7 February 1998 (1998-02-07), pages 253-266, XP000766997 ISSN: 0022-3727 abstract	1-10
X	WO 96 30508 A (RABANI ELY MICHAEL) 3 October 1996 (1996-10-03) page 62-66	1-10
X	SPUDICH J A: "HOW MOLECULAR MOTORS WORK" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 372, 8 December 1994 (1994-12-08), pages 515-518, XP002915204 ISSN: 0028-0836 the whole document	1-10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/20925

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5761960	A	09-06-1998	JP 5065871 A	19-03-1993
			JP 6042604 A	18-02-1994
			DE 69218227 D	17-04-1997
			DE 69218227 T	25-09-1997
			EP 0601185 A	15-06-1994
			WO 9305321 A	18-03-1993
			US 5499547 A	19-03-1996
-----				
WO 9630508	A	03-10-1996	AU 5525296 A	16-10-1996
-----				